Allemani Claudia, Coleman Michel P
Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):4977-4981. doi: 10.1002/cncr.30854.
CONCORD is a programme for the global surveillance of cancer survival. In 2015, the second cycle of the program (CONCORD-2) established long-term surveillance of cancer survival worldwide, for the first time, in the largest cancer survival study published to date. CONCORD-2 provided cancer survival trends for 25,676,887 patients diagnosed during the 15-year period between 1995 and 2009 with 1 of 10 common cancers that collectively represented 63% of the global cancer burden in 2009. Herein, the authors summarize the past, describe the present, and outline the future of the CONCORD programme. They discuss the difference between population-based studies and clinical trials, and review the importance of international comparisons of population-based cancer survival. This study will focus on the United States. The authors explain why population-based survival estimates are crucial for driving effective cancer control strategies to reduce the wide and persistent disparities in cancer survival between white and black patients, which are likely to be attributable to differences in access to early diagnosis and optimal treatment. Cancer 2017;123:4977-81. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
CONCORD是一项全球癌症生存监测计划。2015年，该计划的第二个周期（CONCORD - 2）在有史以来发表的规模最大的癌症生存研究中，首次在全球范围内建立了癌症生存的长期监测。CONCORD - 2提供了1995年至2009年这15年间被诊断患有10种常见癌症之一的25676887名患者的癌症生存趋势，这10种癌症共同构成了2009年全球癌症负担的63%。在此，作者总结了CONCORD计划的过去、描述了其现状并勾勒了其未来。他们讨论了基于人群的研究与临床试验之间的差异，并回顾了基于人群的癌症生存国际比较的重要性。本研究将聚焦于美国。作者解释了为何基于人群的生存估计对于推动有效的癌症控制策略以缩小白人和黑人患者在癌症生存方面广泛且持续存在的差距至关重要，这种差距可能归因于早期诊断和最佳治疗可及性的差异。《癌症》2017年；123:4977 - 81。2017年发表。本文为美国政府作品，在美国属于公共领域。
